Laboratory Tests for Diagnosing Bullous Pemphigoid
Essential Diagnostic Tests
- The British Journal of Dermatology recommends that biopsy specimen should be obtained from perilesional skin (not from the blister itself) for diagnosing bullous pemphigoid 1, 3
- Positive finding in direct immunofluorescence microscopy: Linear (n-serrated) deposits of IgG and/or C3 along the dermoepidermal junction, sometimes IgA and IgE may show similar pattern of deposition 4
- Specimens for histopathology should be taken from early bullae arising on erythematous skin and placed in formalin solution, with typical findings including subepidermal bullae containing eosinophils and/or neutrophils 1, 2, 4
Serological Tests
- Detection of circulating IgG antibasement membrane autoantibodies using NaCl-separated normal human skin (salt-split skin technique) is recommended, with positive finding: IgG antibodies binding to the epidermal side (sometimes both epidermal and dermal) of the split 1, 4
- Detection of anti-BP180 (BPAG2/type XVII collagen) IgG autoantibodies and anti-BP230 (BPAG1-e) IgG autoantibodies by ELISA is recommended, with anti-BP180 ELISA values >27 U/mL indicating increased risk of relapse 1, 4, 5
Diagnostic Algorithm
- Clinical assessment using validated clinical criteria for BP, with diagnosis highly likely in patients with positive DIF when three of four clinical characteristics are present (age >70 years, absence of atrophic scars, absence of mucosal involvement, absence of predominant bullous lesions on neck and head) 1, 2
- First-line laboratory tests include DIF of perilesional skin and histopathology of early intact bulla 1, 2, 3
Laboratory Monitoring During Treatment
- Regular monitoring of complete blood count, erythrocyte sedimentation rate, C-reactive protein, creatinine, blood electrolytes, fasting glucose, liver function tests, and serum albumin is recommended 6
- Regular monitoring of anti-BP180 IgG by ELISA can help assess disease activity and predict relapse 5